- Home
- IQI vs CATX Comparison
IQI vs CATX Comparison
Compare IQI & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$3.83
Company Overview
Basic Information| Metric | IQI | CATX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.2M | 497.9M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IQI | CATX |
|---|---|---|
| Price | $9.71 | $3.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 119.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.06 | $1.96 |
| 52 Week High | $10.42 | $6.16 |
Technical Indicators
Market Signals| Indicator | IQI | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 43.57 |
| Support Level | $9.65 | $3.50 |
| Resistance Level | $10.04 | $3.89 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 20.59 | 41.14 |
Price Performance
Historical Comparison IQI
CATX
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.